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Clinical dermatology as a specialty of medicine has made major strides over the 
past several decades, and major advances in both diagnostic and therapeutic 
management of skin diseases have benefited patients. The progress in clinical 
dermatology to a large extent has relied on the robust academic infrastructure 
developed in recent decades, and we argue that this process has been significantly 
enhanced by technical innovations in molecular medicine and the integration of 
cutaneous biology research into the global biomedical research enterprise.
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Prologue
Today’s dermatology, a premiere 
medical and surgical specialty, is more 
popular than ever as a career choice for 
graduating medical students. Although 
it is one of the smaller specialties of 
medicine (for example, in the United 
States, only about 1.5% of physicians 
are dermatologists), well over 600 
applicants competed for the available 
300 or so residency positions in the 
most recent match. The reasons for the 
popularity of dermatology are many. 
One is that it is a varied specialty, with 
a number of subspecialties; this allows 
individuals to match their interests and 
talents to diverse and variegated fields 
of practice. Progress made in diagnos-
tic and therapeutic management of 
dermatological conditions can provide 
instant job satisfaction, and, in fact, 
dermatologists in general are very sat-
isfied with their specialty choice. Of 
course, dermatology has also been 
touted as a specialty of “controllable 
lifestyle,” providing both comfortable 
practice arrangements and adequate 
compensation (Richtel, 2004).
How did dermatology become 
so advanced and popular? It is clear 
that improved techniques of derma-
tologic surgery and advances in laser 
technology with the advent of cosmetic 
dermatology have contributed to the 
success and popularity of the specialty. 
However, one could argue that the 
progress in modern clinical derma-
tology has been aided by the robust 
research base that has been devel-
oped over the past several decades. In 
this context, it is clear that the rise of 
dermatology and cutaneous biology 
research has benefited, and will con-
tinue to do so, from its close integration 
into the global biomedical research 
enterprise.
Past
Cutaneous biology research has only 
relatively recently become an integral 
part of dermatology practice. Up to and 
until the early decades of the twentieth 
century, dermatology was a clinical 
specialty that relied primarily on visual 
pattern recognition and histopatho-
logical examination of the skin. The 
few available treatments were largely 
empirical, perhaps not that effective, 
and certainly not evidence based. 
Dermatological research was epito-
mized by descriptive reports of unusual 
cases. Only a few academic dermatol-
ogy programs were actively conducting 
laboratory research, and in most cases 
the research units were limited to one 
or few individuals. Often these indi-
viduals were poorly connected to the 
biological research community at large, 
and in many cases they were utilizing 
tools that were outdated relative to the 
standard of their times. Of course, there 
were exceptions, and some individuals 
“single-handedly” advanced the field. 
As an example, Stephen Rothman, a 
Hungarian-trained physician-scientist 
who started his academic career in 
Germany and then established himself 
at the University of Chicago, was one 
of the early pioneers of dermatological 
research (Rothman, 1954) (Figure 1). 
Also, a few individuals working outside 
of established dermatology institutions 
made seminal discoveries impact-
ing dermatology, including studies by 
William Montagna on skin structure 
and function (Montagna, 1956) (Figure 
1). His work, which was conducted in 
the later years at the Oregon Regional 
Primate Center, provided significant 
insight into the development of the skin 
and its appendages.
The scope and depth of skin research 
shifted appreciably during the middle 
part of the past century, when more 
dermatologists received basic science 
training and university-based, research-
intensive medical centers started 
developing active investigative units 
focusing on cutaneous biology and der-
matological disorders. These centers 
were able to interface with research 
being conducted in other medical spe-
cialties and leverage the expertise and 
the research environment provided 
by multi disciplinary medical centers. 
The paradigm of such interdisciplinary 
interactions is, of course, the National 
Institutes of Health (NIH), which traces its 
roots to 1887, with subsequent develop-
ment of the National Institute of Arthritis 
and Musculoskeletal and Skin Diseases 
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in 1986. It is clear that the progress made 
in autoimmune blistering diseases and 
in cutaneous immunity by the investi-
gators at the NIH Dermatology Branch 
broadly benefited from the expertise of 
researchers in other  NIH laboratories 
(Figure 2). At the same time, dermatology 
researchers working within the National 
Cancer Institute were able to apply mod-
ern cancer research tools to investigate 
epidermal biology and cutaneous oncol-
ogy in the context of the larger National 
Cancer Institute research enterprise.
In time, several research-intensive 
medical centers began developing 
active research within dermatology 
departments across the country. An 
example of a vibrant and success-
ful dermatology research unit is the 
one directed by Thomas Fitzpatrick 
at Massachusetts General Hospital at 
Harvard University, and this success 
story was repeated in many medical 
universities around the world, both 
public and private (Figure 3). These 
efforts were supported by robust fund-
ing, often in the form of large center 
grants, such as for program projects 
and skin disease research centers, from 
the NIH, the Wellcome Trust, and oth-
ers. In the United States, these efforts 
benefited from the influx of a cadre of 
ambitious, talented, and hard-work-
ing postdoctoral fellows from foreign 
countries, particularly Japan, Korea, 
and Europe. In turn, established faculty 
from the United States had the oppor-
tunity to spend sabbaticals abroad, 
thus contributing to the international 
exchange of ideas to the benefit of der-
matologic research.
In developing cutaneous biology 
research centers, dermatology residency 
training was combined effectively with 
basic science education and laboratory 
work, made possible by the residency 
training program requirements, which 
at that time stipulated that up to 50% 
of the residency training time could be 
spent in research. This is in stark con-
trast, of course, to the current American 
Board of Dermatology rules, which 
restrict elective time—including for 
research—to three months per three 
year training period. In recognition of 
the importance of basic research and 
clinical investigation, the board has cre-
ated the Investigative/Academic Training 
Track (“two plus two”) for residents 
whose career plans involve a primary 
commitment to investigative or aca-
demic dermatology. This allows for addi-
tional training in research, but it requires 
an extra year of training in the program.
Present
Cutaneous biology research today 
remains a vibrant enterprise that con-
tinues to thrive at the interface of clini-
cal dermatology and the biomedical 
research community at large (Figure 4). 
Multidisciplinary dermatologic research 
units function in a number of medical 
centers with strong support from the 
NIH, the Dermatology Foundation, and 
other institutional and philanthropic 
sources. Cutaneous biology research 
has become exceedingly multidisci-
plinary, and the technologies and strate-
gies of these centers are often borrowed 
from the playbook of basic science 
departments or from research units in 
other medical specialties through inter-
active cooperative arrangements. 
The sophistication of dermatologi-
cal research is amply demonstrated by 
the extensive use of molecular biology 
approaches to map genes underlying 
not only single-gene dermatological 
disorders but also multifactorial con-
ditions, such as psoriasis, alopecia 
areata, and vitiligo (Coto et al., 2011; 
Petukhova et al., 2011; Spritz, 2011). 
In addition, investigators focusing on 
heritable skin diseases have rapidly 
adopted cutting-edge diagnostic and 
therapeutic approaches, as exempli-
fied by next-generation sequencing, 
induced pluripotent stem cell technolo-
gies, and stem cell therapy currently 
being developed for clinical use (Itoh 
et al., 2011; Lai-Cheong and McGrath, 
2011; Tolar et al., 2011; Uitto, 2011). 
Pharmaceutical approaches to the 
management of skin diseases have also 
become much more diverse. A case 
in point are highly effective biologics, 
particularly monoclonal antibodies 
with immunomodulatory properties, 
to treat autoinflammatory skin condi-
tions (Weger, 2010). These examples 
highlight how dermatologic research 
Figure 1. Pioneers of cutaneous biology 
research. (Left) Stephen Rothman, MD; (right) 
William Montagna, PhD. Photographs provided 
by the Society for Investigative Dermatology.
Figure 2. aerial view of the national Institutes of Health (nIH) Biomedical research campus 
at Bethesda, maryland. The NIH exemplifies the opportunities for interdisciplinary research that 
have allowed investigative dermatology to interface with the global biomedical research complex. 
Photograph provided by Hung Tseng and the Office of Communications and Public Liaison, National 
Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH.
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both in basic science and in the trans-
lational arena has direct and broad 
impact on our patients suffering from 
skin diseases.
Future
The successful trajectory of dermato-
logical research is threatened by global 
challenges to the entire biomedical 
research enterprise. This is clearly 
evident, particularly in the United 
States, where more well-trained der-
matologists interested in research are 
needed to maintain the momentum of 
dermatology and cutaneous biology. 
However, only a small fraction of grad-
uating dermatology residents choose 
an intellectually rewarding career in 
academic medicine. This trend is aggra-
vated by the fiscal uncertainties threat-
ening not only the research enterprise 
in the United States at large but also 
dermatological research. The current 
fiscal year (2011) is distinguished as 
the first budget period in NIH history 
in which the actual funding levels have 
been reduced relative to the previous 
funding period. An uncertain political 
climate and variegating fiscal priori-
ties of the government have over recent 
years made NIH support much more 
competitive to obtain. This is not only 
a challenge for established investiga-
tors but outright discouraging to those 
at the early stages of their training who 
are contemplating an academic career 
in research. At the same time, there is 
less support for foreign fellows in the 
United States, and Japanese and Korean 
postdocs increasingly go to Europe 
while the Europeans stay home for their 
advanced research training.
Similar trends in many areas of 
basic science research are evident in 
some European countries, although 
the European Union overall has been 
supportive of its research enterprise. 
At the global level, it is clear that the 
priorities of several Asian countries 
are different from those in the United 
States. The research enterprises of 
China, South Korea, and Singapore 
have reached new heights, and their 
governments continue to invest heavily 
in biomedical research, including 
dermatology and cutaneous biol-
ogy. This shift is particularly evident 
in China and, on a smaller scale, in 
Singapore, where entire new univer-
sity cities, research complexes, and 
medical centers are being built at a 
rapid pace. These trends in the global 
research infrastructure are reflected 
already in research output as judged 
by firm metrics, such as tracking the 
submission rate of manuscripts from 
different countries to the Journal of 
Investigative Dermatology. For exam-
ple, whereas the total number of unso-
licited submissions over the past four 
years (2007–2010) increased from 899 
to 929 (~3%), the submissions from 
North America declined from 278 to 
238 (−14%); at the same time, submis-
sions from Asia and Mideast regions 
increased from 186 to 253 (+36%). In 
particular, the number of submissions 
from China and South Korea almost 
doubled during the same time peri-
od (from 26 to 47 and from 36 to 51, 
respectively) (Bergstresser, 2011).
the path forward
What can be done to retool dermato-
logical research in the United States in 
the challenging times ahead? Because 
it is unlikely that any single measure 
can successfully counter the fiscal 
realities, a multipronged approach is 
needed. One avenue is to attract addi-
tional financial support by developing a 
strong commercial/university laboratory 
Figure 3. research faculty fellows and staff of the Department of Dermatology and cutaneous 
Biology at Jefferson medical college in Philadelphia, Pennsylvania, in 2000. The dermatology 
research unit was, and continues to be, an integral part of the Jefferson Institute of Molecular Medicine, 
an umbrella of multidisciplinary research efforts at Thomas Jefferson University. This has allowed 
investigative dermatology to leverage the strategies and technologies of molecular biology from other 
medical subspecialties and basic science units. The authors of this article are indicated with red stars: 
(left) Jouni Uitto, MD, PhD; (right) Ulrich Rodeck, MD, PhD.
Figure 4. Venn diagram positioning investigative dermatology at the interface of clinical dermatology and 
global biomedical research enterprise, and examples of critical contemporary factors impacting these spheres.
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interface with an appropriate fund-
ing base and using a business model 
with milestones, stop/go decision mak-
ing, and clearly articulated goals for 
translational end points. This model 
becomes increasingly viable as mech-
anism-based approaches to diagnosis 
and treatment of skin conditions are 
within reach. Better understanding of 
disease mechanisms may also facilitate 
the repurposing of existing drugs for der-
matological applications, potentially as 
topical agents. Reformulating existing 
drugs, with established safety profiles, in 
this manner may widen their thera peutic 
window with substantial benefit for 
dermatological applications and abbre-
viated paths to regulatory approval. A 
vibrant research community will play an 
important role in expanding and explor-
ing opportunities in this area. 
Another area of shared academic 
and commercial interest is the analysis 
of molecular mechanisms of adverse 
events affecting the skin, associated 
with conventional and “targeted” anti-
tumor agents rapidly being integrated 
into the management of malignant dis-
eases. This area too can benefit greatly 
from a combination of mechanistic and 
interventional strategies to improve out-
comes. Dermatologists trained both in 
clinical practice and in basic research 
will provide a vital intellectual and 
physical link between mechanism-based 
investigations and clinical trials cen-
tered on these efforts. In this context, the 
move of dermatologist-scientists from 
academia to pharmaceutical industry 
can contribute to the dissemination of 
knowledge and techniques relevant to 
the development of treatment modalities 
for skin diseases.
One area in which all researchers 
should actively participate is political 
advocacy in attempts to educate the 
politicians and decision makers, as 
well as the public at large, about the 
benefits of biomedical research already 
achieved and within reach in the near 
future. After all, the federal budget in 
the United States and elsewhere is all 
about prioritization of resources for dif-
ferent segments of society. Scientists 
can help to focus attention on research 
as an engine of medical progress by 
forming coalitions with patient advo-
cacy organizations, powerful lobbying 
groups centered on diagnosis and treat-
ment of specific diseases, including 
those affecting skin (Uitto, 2001; Terry 
et al., 2007). 
We hope that this synopsis serves 
as a general call to action, which 
must be followed by specific strategies 
under the leadership of organizations 
such as the Society for Investigative 
Dermatology.
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